Yukitaka Ueki

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Glucose Tolerance, Insulin Secretion, and Insulin Sensitivity in Nonobese and Obese Japanese Subjects

Kazunari Matsumoto, Seibei Miyake, Mayumi Yano et al. · Diabetes Care · 1997 · 213 citations

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Increased nitric oxide levels in patients with rheumatoid arthritis.

Yukitaka Ueki, Seibei Miyake, Yuko Tominaga et al. · PubMed · 1996 · 185 citations

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

Atsushi Ogata, Kazuhide Tanimura, Toyohiko Sugimoto et al. · Arthritis Care & Research · 2013 · 137 citations · Full text